- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1142090-23-0] GSK2256294A
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19644 |
| Brand: | MCE |
| CAS: | 1142090-23-0 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 447.46 |
| Molecular Formula | C21H24F3N7O |
| SMILES | O=C([C@H]1C[C@@H](NC2=NC(NC)=NC(C)=N2)CCC1)NCC3=CC=C(C#N)C=C3C(F)(F)F |
2 Publications Citing Use of MCE
Summary
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH) . GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC 50 s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease [1] .
IC50 & Target
IC50: 27 pM (recombinant human sEH), 61 pM (rat sEH orthologs), 189 pM (murine sEH orthologs) [1]
In Vitro
GSK2256294A (300 pM-10 μM; 2 h) inhibits the conversion of 14,15-EET-d11 to 14,15-DHET-d11 in human, rat and mouse whole blood [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GSK2256294A (5-30 mg/kg; p.o. twice daily 5 days/week for two weeks) inhibits the generation and maintenance of pulmonary inflammation in cigarette smoke-exposed mice
[1]
.
GSK2256294A (30 mg/kg; p.o. twice daily for 8 days) decreases pulmonary inflammation in cigarette smoke-exposed mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Mice exposed to cigarette smoke 5 days/week for 2 weeks [1] |
| Dosage: | 5 and 30 mg/kg |
| Administration: | Oral gavage; 5 and 30 mg/kg twice daily 5 days/week; for 2 weeks |
| Result: | Dose-dependently inhibited numbers of BAL fluid total cells, neutrophils, macrophages and the keratinocyte chemoattractant (KC) levels in lung tissue. |
| Animal Model: | Mice exposed to cigarette smoke 5 days/week for 2 weeks [1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral gavage; 30 mg/kg twice daily; for 8 days |
| Result: | Significantly reduced neutrophils, macrophages and pulmonary inflammation in cigarette smoke-exposed mice. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02006537 | GlaxoSmithKline |
Pulmonary Disease, Chronic Obstructive
|
January 31, 2014 | Phase 1 |
| NCT01762774 | GlaxoSmithKline |
Pulmonary Disease, Chronic Obstructive
|
January 16, 2013 | Phase 1 |
| NCT03486223 | Vanderbilt University Medical Center|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Diabetes Mellitus|Endocrine System Diseases|Glucose Metabolism Disorders|PreDiabetes|Obesity
|
May 17, 2018 | Phase 2 |
| NCT03318783 | Oregon Health and Science University|Foundation for Anesthesia Education and Research|GlaxoSmithKline |
Subarachnoid Hemorrhage, Aneurysmal|Delayed Cerebral Ischemia|Vasospasm, Cerebral|Endothelial Dysfunction
|
May 2, 2018 | Phase 1|Phase 2 |
| NCT02262689 | GlaxoSmithKline|Parexel |
Pulmonary Disease, Chronic Obstructive
|
January 8, 2015 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 47 mg/mL ( 105.04 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2348 mL | 11.1742 mL | 22.3484 mL |
| 5 mM | 0.4470 mL | 2.2348 mL | 4.4697 mL |
| 10 mM | 0.2235 mL | 1.1174 mL | 2.2348 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.